These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 29074218)
1. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218 [TBL] [Abstract][Full Text] [Related]
2. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Taghibiglou C; Van Iderstine SC; Kulinski A; Rudy D; Adeli K Biochem Pharmacol; 2002 Feb; 63(3):349-60. PubMed ID: 11853686 [TBL] [Abstract][Full Text] [Related]
3. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Tardif JC; Grégoire J; L'Allier PL; Anderson TJ; Bertrand O; Reeves F; Title LM; Alfonso F; Schampaert E; Hassan A; McLain R; Pressler ML; Ibrahim R; Lespérance J; Blue J; Heinonen T; Rodés-Cabau J; Circulation; 2004 Nov; 110(21):3372-7. PubMed ID: 15533865 [TBL] [Abstract][Full Text] [Related]
4. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Post SM; Zoeteweij JP; Bos MH; de Wit EC; Havinga R; Kuipers F; Princen HM Hepatology; 1999 Aug; 30(2):491-500. PubMed ID: 10421659 [TBL] [Abstract][Full Text] [Related]
5. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Llaverías G; Laguna JC; Alegret M Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916 [TBL] [Abstract][Full Text] [Related]
6. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910 [TBL] [Abstract][Full Text] [Related]
7. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Li X; Li J; Feng Y; Cai H; Li YP; Peng T Antiviral Res; 2020 May; 177():104734. PubMed ID: 32057770 [TBL] [Abstract][Full Text] [Related]
8. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Zeisel MB; Crouchet E; Baumert TF; Schuster C Viruses; 2015 Nov; 7(11):5659-85. PubMed ID: 26540069 [TBL] [Abstract][Full Text] [Related]
9. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. von Hahn T; Ciesek S; Manns MP Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851 [TBL] [Abstract][Full Text] [Related]
10. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176 [TBL] [Abstract][Full Text] [Related]
11. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Burnett JR; Telford DE; Barrett PH; Huff MW Biochim Biophys Acta; 2005 Dec; 1738(1-3):10-8. PubMed ID: 16427354 [TBL] [Abstract][Full Text] [Related]
12. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle. McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase. Miyazaki A; Kanome T; Watanabe T Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866 [TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. Shahidi M; Tay ESE; Read SA; Ramezani-Moghadam M; Chayama K; George J; Douglas MW J Gen Virol; 2014 Nov; 95(Pt 11):2468-2479. PubMed ID: 25053565 [TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. Park SB; Boyer A; Hu Z; Le D; Liang TJ Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus resistance to protease inhibitors. Halfon P; Locarnini S J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949 [TBL] [Abstract][Full Text] [Related]
17. Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System. Zhao F; Zhao T; Deng L; Lv D; Zhang X; Pan X; Xu J; Long G J Virol; 2017 Jan; 91(2):. PubMed ID: 27852847 [TBL] [Abstract][Full Text] [Related]